Discovery of a novel metallo-beta-lactamase inhibitor that potentiates meropenem activity against carbapenem-resistant enterobacteriaceae

Everett, M.; Sprynski, N.; Coelho, A.; Castandet, J.; Bayet, M.; Bougnon, J.; Lozano, C.; Davies, D. T.; Leiris, S.; Zalacain, M.; Morrissey, I.; Magnet, S.; Holden, K.; Warn, P.; De Luca, F.; Docquier, Jean-Denis; Lemonniera, M.

doi:10.1128/AAC.00074-18

Article (Scientific journals)

Discovery of a novel metallo-beta-lactamase inhibitor that potentiates meropenem activity against carbapenem-resistant enterobacteriaceae

Everett, M.; Sprynski, N.; Coelho, A. et al.

2018 • In Antimicrobial Agents and Chemotherapy, 62 (5)

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/252547

DOI
10.1128/AAC.00074-18

PubMed
29530861

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

82.pdf

Publisher postprint (938.84 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Carbapenem; Inhibitor; Metallo--lactamase; NDM-1; Resistance; Article; Citrobacter freundii; Enterobacter cloacae; Escherichia coli; Escherichia coli infection; Klebsiella pneumoniae; Morganella morganii; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Meropenem; Microbial Sensitivity Tests

Abstract :

[en] Infections caused by carbapenem-resistant Enterobacteriaceae (CRE) are increasingly prevalent and have become a major worldwide threat to human health. Carbapenem resistance is driven primarily by the acquisition of beta-lactamase enzymes, which are able to degrade carbapenem antibiotics (hence termed carbapenemases) and result in high levels of resistance and treatment failure. Clinically relevant carbapenemases include both serine beta-lactamases (SBLs; e.g., KPC-2 and OXA-48) and metallo-beta-lactamases (MBLs), such as NDM-1. MBL-producing strains are endemic within the community in many Asian countries, have successfully spread worldwide, and account for many significant CRE outbreaks. Recently approved combinations of beta-lactam antibiotics with beta-lactamase inhibitors are active only against SBL-producing pathogens. Therefore, new drugs that specifically target MBLs and which restore carbapenem efficacy against MBL-producing CRE pathogens are urgently needed. Here we report the discovery of a novel MBL inhibitor, ANT431, that can potentiate the activity of meropenem (MEM) against a broad range of MBL-producing CRE and restore its efficacy against an Escherichia coli NDM-1producing strain in a murine thigh infection model. This is a strong starting point for a chemistry lead optimization program that could deliver a first-in-class MBL inhibitor-carbapenem combination. This would complement the existing weaponry against CRE and address an important and growing unmet medical need. © 2018 American Society for Microbiology. All Rights Reserved.

Disciplines :

Microbiology

Author, co-author :

Everett, M.; Antabio SAS, Labège, France

Sprynski, N.; Antabio SAS, Labège, France

Coelho, A.; Antabio SAS, Labège, France

Castandet, J.; Antabio SAS, Labège, France

Bayet, M.; Antabio SAS, Labège, France

Bougnon, J.; Antabio SAS, Labège, France

Lozano, C.; Antabio SAS, Labège, France

Davies, D. T.; Antabio SAS, Labège, France

Leiris, S.; Antabio SAS, Labège, France

Zalacain, M.; Antabio SAS, Labège, France, Zala Drug Discovery Consulting LLC, West Chester, PA, United States

More authors (7 more)

Language :

English

Title :

Discovery of a novel metallo-beta-lactamase inhibitor that potentiates meropenem activity against carbapenem-resistant enterobacteriaceae

Publication date :

2018

Journal title :

Antimicrobial Agents and Chemotherapy

ISSN :

0066-4804

eISSN :

1098-6596

Publisher :

American Society for Microbiology

Volume :

Issue :

Peer reviewed :

Peer Reviewed verified by ORBi

Funders :

Wellcome Trust [GB]

Available on ORBi :

since 13 November 2020

Statistics

Number of views

59 (1 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Miller CP, Bohnhoff M. 1945. Studies on the action of penicillin; development of penicilli resistance by gonococcus. Proc Soc Exp Biol Med 60:354–356. https://doi.org/10.3181/00379727-60-15187P.
Abraham EP, Chain E. 1940. An enzyme from bacteria able to destroy penicillin. Nature 146:837.
Hunter PA, Coleman K, Fisher J, Taylor D. 1980. In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin. J Antimicrob Chemother 6:455–470. https://doi.org/10.1093/jac/6.4.455.
De Koning GA, Tio D, Coster JF, Coutinho RA, Ansink-Schipper MC. 1981. The combination of clavulanic acid and amoxycillin (Augmentin) in the treatment of patients infected with penicillinase producing gonococci. J Antimicrob Chemother 8:81–82.
Bush K, Jacoby GA, Medeiros AA. 1995. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39:1211–1233. https://doi.org/10.1128/AAC.39.6.1211.
Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, Jeremiah C, Loeches B, Machuca I, Jimenez-Martin MJ, Martinez JA, Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos Ramos JC, Rodriguez M, Sanchez-Garcia M, Viale P, Wolff M, Carmeli Y. 2017. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 61:e01964-16. https://doi.org/10.1128/AAC.01964-16.
Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. 2018. Evaluation of the in vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother 62:e01904-17. https://doi.org/10.1128/AAC.01904-17.
Queenan AM, Bush K. 2007. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20:440–458. https://doi.org/10.1128/CMR.00001-07.
Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrish-nan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10:597–602. https://doi.org/10.1016/S1473-3099(10)70143-2.
Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 2009. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53:5046–5054. https://doi.org/10.1128/AAC .00774-09.
Li JJ, Munoz-Price LS, Spychala CN, DePascale D, Doi Y. 2016. New Delhi metallo-beta-lactamase-1-producing Klebsiella pneumoniae, Florida, USA. Emerg Infect Dis 22:744–746. https://doi.org/10.3201/eid2204.151176.
Savov E, Politi L, Spanakis N, Trifonova A, Kioseva E, Tsakris A. 6 September 2017. NDM-1 hazard in the Balkan States: evidence of the first outbreak of NDM-1-producing Klebsiella pneumoniae in Bulgaria. Mi-crob Drug Resist. https://doi.org/10.1089/mdr.2017.0230.
Haciseyitoglu D, Dokutan A, Abulaila A, Erdem F, Cag Y, Ozer S, Aktas Z. 2017. The first Enterobacter cloacae co-producing NDM and OXA-48 carbapenemases and interhospital spread of OXA-48 and NDM-producing Klebsiella pneumoniae in Turkey. Clin Lab 63:1213–1222. https://doi.org/10.7754/Clin.Lab.2017.170120.
Hussein NH. 1 September 2017. Emergence of NDM-1 among carbapenem-resistant Klebsiella pneumoniae in Iraqi hospitals. Acta Microbiol Immunol Hung https://doi.org/10.1556/030.64.2017.026.
Dong F, Lu J, Wang Y, Shi J, Zhen JH, Chu P, Zhen Y, Han SJ, Guo YL, Song WQ. 2017. A five-year surveillance of carbapenemase-producing Klebsiella pneumoniae in a pediatric hospital in China reveals increased predominance of NDM-1. Biomed Environ Sci 30:562–569.
Singh-Moodley A, Perovic O. 2016. Antimicrobial susceptibility testing in predicting the presence of carbapenemase genes in Enterobacteriaceae in South Africa. BMC Infect Dis 16:536. https://doi.org/10.1186/s12879-016-1858-7.
Bocanegra-Ibarias P, Garza-Gonzalez E, Morfin-Otero R, Barrios H, Villarreal-Trevino L, Rodriguez-Noriega E, Garza-Ramos U, Petersen-Morfin S, Silva-Sanchez J. 2017. Molecular and microbiological report of a hospital outbreak of NDM-1-carrying Enterobacteriaceae in Mexico. PLoS One 12:e0179651. https://doi.org/10.1371/journal.pone.0179651.
Khan AU, Maryam L, Zarrilli R. 2017. Structure, genetics and worldwide spread of New Delhi metallo-beta-lactamase (NDM): a threat to public health. BMC Microbiol 17:101. https://doi.org/10.1186/s12866-017-1012-8.
Liu Z, Wang Y, Walsh TR, Liu D, Shen Z, Zhang R, Yin W, Yao H, Li J, Shen J. 2017. Plasmid-mediated novel blaNDM-17 gene encoding a carbapenemase with enhanced activity in a sequence type 48 Escherichia coli strain. Antimicrob Agents Chemother 61:e02233-16. https://doi.org/10 .1128/AAC.02233-16.
Dortet L, Poirel L, Nordmann P. 2014. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res Int 2014:249856. https://doi.org/10.1155/2014/249856.
Horsfall LE, Garau G, Lienard BM, Dideberg O, Schofield CJ, Frere JM, Galleni M. 2007. Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila. Antimicrob Agents Chemother 51:2136–2142. https://doi.org/10.1128/AAC.00866-06.
Pettinati I, Brem J, Lee SY, McHugh PJ, Schofield CJ. 2016. The chemical biology of human metallo-beta-lactamase fold proteins. Trends Biochem Sci 41:338 –355. https://doi.org/10.1016/j.tibs.2015.12.007.
Ordooei Javan A, Shokouhi S, Sahraei Z. 2015. A review on colistin nephrotoxicity. Eur J Clin Pharmacol 71:801–810. https://doi.org/10.1007/s00228-015-1865-4.
Dixit D, Madduri RP, Sharma R. 2014. The role of tigecycline in the treatment of infections in light of the new black box warning. Expert Rev Anti Infect Ther 12:397–400. https://doi.org/10.1586/14787210.2014.894882.
Choi JJ, McCarthy MW. 2018. Cefiderocol: a novel siderophore cephalo-sporin. Expert Opin Invest Drugs 27:193–197. https://doi.org/10.1080/13543784.2018.1426745.
Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spell-berg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG, Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA. 2017. Can ceftazidime-avibactam and aztreonam overcome beta-lactam resistance conferred by metallo-beta-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother 61:e02243-16. https://doi.org/10.1128/AAC.02243-16.
Reck F, Bermingham A, Blais J, Capka V, Cariaga T, Casarez A, Colvin R, Dean CR, Fekete A, Gong W, Growcott E, Guo H, Jones AK, Li C, Li F, Lin X, Lindvall M, Lopez S, McKenney D, Metzger L, Moser HE, Prathapam R, Rasper D, Rudewicz P, Sethuraman V, Shen X, Shaul J, Simmons RL, Tashiro K, Tang D, Tjandra M, Turner N, Uehara T, Vitt C, Whitebread S, Yifru A, Zang X, Zhu Q. 2018. Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae—identification of LYS228. Bioorg Med Chem Lett 28:748–755. https://doi.org/10.1016/j.bmcl.2018.01.006.
Arjomandi OK, Hussein WM, Vella P, Yusof Y, Sidjabat HE, Schenk G, McGeary RP. 2016. Design, synthesis, and in vitro and biological evaluation of potent amino acid-derived thiol inhibitors of the metallo-beta-lactamase IMP-1. Eur J Med Chem 114:318–327. https://doi.org/10.1016/j.ejmech.2016.03.017.
Klingler FM, Wichelhaus TA, Frank D, Cuesta-Bernal J, El-Delik J, Muller HF, Sjuts H, Gottig S, Koenigs A, Pos KM, Pogoryelov D, Proschak E. 2015. Approved drugs containing thiols as inhibitors of metallo-beta-lactamases: strategy to combat multidrug-resistant bacteria. J Med Chem 58:3626–3630. https://doi.org/10.1021/jm501844d.
Yusof Y, Tan DT, Arjomandi OK, Schenk G, McGeary RP. 2016. Captopril analogues as metallo-beta-lactamase inhibitors. Bioorg Med Chem Lett 26:1589–1593. https://doi.org/10.1016/j.bmcl.2016.02.007.
Brem J, van Berkel SS, Aik W, Rydzik AM, Avison MB, Pettinati I, Umland KD, Kawamura A, Spencer J, Claridge TD, McDonough MA, Schofield CJ. 2014. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-beta-lactamase inhibition. Nat Chem 6:1084–1090. https://doi.org/10.1038/nchem.2110.
Liu XL, Yang KW, Zhang YJ, Ge Y, Xiang Y, Chang YN, Oelschlaeger P. 2016. Optimization of amino acid thioesters as inhibitors of metallo-beta-lactamase L1. Bioorg Med Chem Lett 26:4698–4701. https://doi.org/10.1016/j.bmcl.2016.08.048.
Brem J, Cain R, Cahill S, McDonough MA, Clifton IJ, Jimenez-Castellanos JC, Avison MB, Spencer J, Fishwick CW, Schofield CJ. 2016. Structural basis of metallo-beta-lactamase, serine-beta-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat Commun 7:12406. https://doi.org/10.1038/ncomms12406.
Yang SK, Kang JS, Oelschlaeger P, Yang KW. 2015. Azolylthioacetamide: a highly promising scaffold for the development of metallo-beta-lactamase inhibitors. ACS Med Chem Lett 6:455–460. https://doi.org/10.1021/ml500534c.
King AM, Reid-Yu SA, Wang W, King DT, De Pascale G, Strynadka NC, Walsh TR, Coombes BK, Wright GD. 2014. Aspergillomarasmine A overcomes metallo-beta-lactamase antibiotic resistance. Nature 510: 503–506. https://doi.org/10.1038/nature13445.
Matsuura A, Okumura H, Asakura R, Ashizawa N, Takahashi M, Kobayashi F, Ashikawa N, Arai K. 1993. Pharmacological profiles of aspergilloma-rasmines as endothelin converting enzyme inhibitors. Jpn J Pharmacol 63:187–193. https://doi.org/10.1254/jjp.63.187.
Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 8th ed. Approved standard M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
Docquier JD, Lamotte-Brasseur J, Galleni M, Amicosante G, Frere JM, Rossolini GM. 2003. On functional and structural heterogeneity of VIM-type metallo-beta-lactamases. J Antimicrob Chemother 51:257–266. https://doi.org/10.1093/jac/dkg067.